Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Other Accumulated Expenses for 3 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 95.04% to $73000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $73000.0, a 95.04% decrease, with the full-year FY2025 number at $73000.0, down 95.04% from a year prior.
  • Other Accumulated Expenses was $73000.0 for Q4 2025 at Artiva Biotherapeutics, down from $442000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q4 2024 to a low of $73000.0 in Q1 2025.
  • A 3-year average of $651714.3 and a median of $442000.0 in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 32.73% in 2024, then plummeted 95.04% in 2025.
  • Artiva Biotherapeutics' Other Accumulated Expenses stood at $1.1 million in 2023, then skyrocketed by 32.73% to $1.5 million in 2024, then tumbled by 95.04% to $73000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Other Accumulated Expenses are $73000.0 (Q4 2025), $442000.0 (Q3 2025), and $73000.0 (Q2 2025).